angiotensin ii has been researched along with mdl 100240 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, T; Brunner-Ferber, F; Gardiner, SM; Kemp, PA | 1 |
| Biollaz, J; Brunner, HR; Brunner-Ferber, F; Buclin, T; Nussberger, J; Rousso, P | 1 |
| Biollaz, J; Brunner, HR; Brunner-Ferber, F; Buclin, T; Décosterd, LA; La Roche, SD; Nussberger, J; Rousso, P | 1 |
| Agabiti-Rosei, E; Bova, S; Neri, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP; Sacchetto, A | 1 |
| Agabiti-Rosei, E; Bova, S; Cavallin, M; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP | 1 |
2 trial(s) available for angiotensin ii and mdl 100240
| Article | Year |
|---|---|
Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers.
Topics: Adult; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Area Under Curve; Benzazepines; Blood Pressure; Double-Blind Method; Enzyme Inhibitors; Humans; Male; Neprilysin; Placebos; Pyridines; Reference Values | 1998 |
Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Endocrine System; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney; Male; Neprilysin; Peptidyl-Dipeptidase A; Posture; Pyridines; Reference Values; Renal Plasma Flow, Effective; Safety; Stereoisomerism | 1999 |
3 other study(ies) available for angiotensin ii and mdl 100240
| Article | Year |
|---|---|
Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Benzazepines; Bradykinin; Endothelin-1; Hemodynamics; Male; Neprilysin; Protease Inhibitors; Pyridines; Rats | 1997 |
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Aorta; Benzazepines; Blood Pressure; Body Weight; Cardiovascular Diseases; Hypertension; In Vitro Techniques; Male; Neprilysin; Organ Size; Pyridines; Ramipril; Rats; Vasoconstriction | 2002 |
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
Topics: Adrenomedullin; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Pressure; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Heart; Hypertension; Male; Models, Cardiovascular; Neprilysin; Organ Size; Peptides; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Receptors, Bradykinin; Severity of Illness Index; Systole; Treatment Outcome; Vasoconstrictor Agents | 2002 |